AR and polycystic ovary syndrome: The exact molecular mechanism of lupeol in PCOS cases is not fully understood yet, however, it seems lupeol as a known inhibitor of androgen receptors (AR) more likely competes with DHEA to bind to AR and consequently reduce the PCOS-related structural (atretic follicles and fibrosis) and also functional alterations (alterations in hormonal situation and low outcome of IVF).